Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Forsteo ® (teriparatide)
Forsteo® (teriparatide): Switching from Antiresorptive
A wash out period between end of antiresorptive treatment and start of Forsteo is not required. A particular recommendation for switching is not available and the decision remains at the discretion of prescribing physician.
Decisions regarding when to initiate a new treatment are up to the discretion of the physician, incorporating clinical judgment according to institutional guidelines and/or clinical practice.
Forsteo is not indicated in combination with an antiresorptive.1
Treatment with an antiresorptive should be discontinued before initiating Forsteo, since the clinical benefit of using teriparatide in combination with a bisphosphonate or denosumab has not been established.
1. Forsteo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Date of Last Review: November 14, 2019